Condoliase - Seikagaku Corporation

Drug Profile

Condoliase - Seikagaku Corporation

Alternative Names: C-ABC; ChABC; Chondroitin-sulfate-ABC endolyase; Chondroitinase ABC; SI-6603

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seikagaku Corporation
  • Class Chondroitin lyases
  • Mechanism of Action Chondroitin sulfate proteoglycan modulators; Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Intervertebral disc displacement

Most Recent Events

  • 07 Nov 2017 Seikagaku Corporation completes a phase III trial for Intervertebral disc displacement in USA (Intraspinal, Injection) (NCT01941563)
  • 07 Nov 2017 Seikagaku intends to initiate a III, double-blind clinical trial for Intervertebral disc displacement in USA at an early date
  • 18 May 2017 Condoliase is still under regulatory review for Intervertebral disc displacement in Japan (Parenteral) (Seikagaku pipeline May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top